HAE

HAEMONETICS CORP HAE

NYSEMid CapHealthcare

13F Pro quality score

Rank #1,546 of 2,925

Why it scores 52Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$339.38M

Quarter to Jun 27

Net income

$33.01M

Quarter to Jun 27

Free cash flow

$44.42M

Quarter to Jun 27

Operating margin

16.9%

Quarter to Jun 27

Top Institutional Holders

as of Q2 2026
$4.39B total
BlackRock, Inc.
$505.26M-3.5%
Neuberger Berman Group LLC
$313.47M+17.4%
VANGUARD PORTFOLIO MANAGEMENT LLC
$190.98M-0.5%
LINDEN ADVISORS LP
$179.23M-6.6%
AQR CAPITAL MANAGEMENT LLC
$165.02M-32.5%
ARIEL INVESTMENTS, LLC
$154.57MNew
STATE STREET CORP
$154.49M+14.8%
VANGUARD CAPITAL MANAGEMENT LLC
$154.47M-1.5%
DIMENSIONAL FUND ADVISORS LP
$118.89M+19.5%
CITADEL ADVISORS LLC
$113.26M+485.0%
GEODE CAPITAL MANAGEMENT, LLC
$96.56M+5.6%
River Road Asset Management, LLC
$96.42M-3.2%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$86.65M-16.5%
T. Rowe Price Investment Management, Inc.
$82.60M+84.4%
GOLDMAN SACHS GROUP INC
$78.45M+9.8%
UBS Group AG
$73.75M+86.7%
Invesco Ltd.
$72.81M0.0%
FRANKLIN RESOURCES INC
$62.63M-0.1%
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/
$62.32M-1.2%
ROYAL BANK OF CANADA
$58.52M-9.1%
MILLENNIUM MANAGEMENT LLC
$58.49MNew
Allspring Global Investments Holdings, LLC
$57.27M-14.1%
DEUTSCHE BANK AG\
$48.28M+21.8%
PRICE T ROWE ASSOCIATES INC /MD/
$47.76M+51.5%
NORTHERN TRUST CORP
$47.37M+9.0%
See all 366 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2027
EDGAR

Net Income

Q1 2027
EDGAR

EPS (Diluted)

Q1 2027
EDGAR

Operating Margin

Q1 2027
EDGAR

ROIC

Q1 2027
EDGAR

Free Cash Flow

Q1 2027
EDGAR

Debt/Equity

Q1 2027
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/HAE

Earnings Per Share

13fpro.ai/company/HAE

Loading ratio trend…

Companies similar to HAE

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

HAE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About HAEMONETICS CORP (HAE): stock profile, AI score and financials

HAEMONETICS CORP (HAE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HAE at 51.5/100 on a composite quality score built from its SEC filings, placing it at rank #1,546 of 2,925 stocks — the bottom half of the AI-ranked universe. HAE scores in the top quartile across earnings quality (92.5), free cash flow (75.3). Areas of concern include revenue growth (27.1) and institutional flow (30.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 35.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2027), HAEMONETICS CORP reports quarterly revenue of $339.4M, net income of $33.0M, an operating margin of 16.9%. HAE trades on the NYSE exchange and files with the SEC under CIK 313143. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HAE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HAEMONETICS CORP directly from SEC EDGAR.

SEC EDGAR: CIK 313143 →